Publicado 07/12/2021 12:45CET
- Comunicado -

R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation

R-Biopharm
R-Biopharm - R-BIOPHARM
R-Biopharm
   

Darmstadt, 7 December 2021 – R-Biopharm, an international specialist in clinical diagnostics, announces that the company’s RIDAGENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) Regulations 2021 (“CTDA”). R-Biopharm will now work to resume the sale of the product in the UK.

   

RIDAGENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDAGENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRp gene in all currently known variants and mutations of the COVID 19 virus.

   

Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDAGENE Flu & SARS-CoV-2 test was approved and added to the CTDA register and our customers will continue to be able to distinguish between the flu and an infection with the Corona virus.“

   

Press contact:

Simone Feiler

Head of Corporate Brand

Communication

   

https://r-biopharm.com

https://r-biopharm.com/news-press/

   

R-Biopharm AG

An der neuen Bergstraße 17

64297 Darmstadt, Germany

Tel.: 0 61 51 - 81 02-538

Mobile: 0 160 - 55 273 60

Fax: 0 61 51 - 81 02-40

Email: s.feiler@r-biopharm.de

Mejora la comunicación de tu empresa con Europa Press Comunicación